Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ER niacin/laropiprant added to ongoing lipid-modifying therapy in dyslipidemia
2008-000465-37Phase 3Terminated
- Sponsor
- Merck & Co.
- Start
- Apr 2008
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of laropiprant + niacin in dyslipidemia and hypercholesterolemia (2 arms), sponsored by Merck & Co. Primary endpoint: Percent change from baseline in LDL-C at Week 12. Started Apr 2008; status: terminated.
02
Drugs
laropiprant + niacin
03
Conditions
dyslipidemiahypercholesterolemia
Beyond the preview
Go deeper on 2008-000465-37.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2008-000465-37.